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Summary
 
Members of the tumor necrosis factor (TNF) family induce pleiotropic biological responses, in-
cluding cell growth, differentiation, and even death. Here we describe a novel member of the
TNF family, designated BAFF (for B cell activating factor belonging to the TNF family),
which is expressed by T cells and dendritic cells. Human BAFF was mapped to chromosome
13q32-34. Membrane-bound BAFF was processed and secreted through the action of a pro-
tease whose specificity matches that of the furin family of proprotein convertases. The expres-
sion of BAFF receptor appeared to be restricted to B cells. Both membrane-bound and soluble
BAFF induced proliferation of anti-immunoglobulin M–stimulated peripheral blood B lym-
phocytes. Moreover, increased amounts of immunoglobulins were found in supernatants of
germinal center–like B cells costimulated with BAFF. These results suggest that BAFF plays an
important role as costimulator of B cell proliferation and function.
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embers of the TNF cytokine family are critically in-
volved in the regulation of inflammation, of the im-
mune response to infections, and of tissue homeostasis (1).
The family members are type II membrane proteins that can
act in a membrane-bound form or as proteolytically pro-
cessed, soluble cytokines in an autocrine, paracrine, or endo-
crine manner (1). Binding of the ligands to their respective
receptors induces oligomerization, initiating downstream
signaling events.
Signaling pathways stimulated by TNF ligand members
are diverse, including the activation of caspases, the translo-
cation of nuclear factor (NF)-
 
k
 
B,
 
1
 
 or the activation of mito-
gen-activated protein kinases such as c-Jun NH
 
2
 
-terminal
kinase (JNK) or extracellular signal regulatory kinase (ERK)
(1). Thus, TNF-related ligands can lead to apoptosis, differ-
entiation, or proliferation. Presently 16 members of the
TNF-cytokine family have been described, several among
them having important regulatory roles in function and de-
velopment of the immune system. For instance, TNF acts
as an inflammatory cytokine coordinating host defenses in
response to infection (2). The lymphotoxin (LT) system is
crucial in the development of peripheral lymphoid organs
and the organization of splenic architecture (3, 4). Fas ligand
(FasL, CD95L), TNF, and CD30L are responsible for
TCR-mediated apoptosis of T cells and of immature thy-
mocytes (5–7). Several of the TNF members and their re-
ceptors, in conjunction with TCR stimulation, also en-
hance T cell proliferation. Therefore, upregulation of TNF
cytokine members and their receptors by TCR-induced
signals can provide an autocrine costimulatory mechanism
to increase the lymphocyte’s own proliferation after stimu-
lation with the antigen. However, upregulation of TNF-
related ligands on T cells is also important for the activation
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Abbreviations used in this paper:
 
 aa, amino acid(s); APRIL, a proliferation in-
ducing ligand; BAFF, B cell activating factor belonging to the TNF family;
EST, expressed sequence tag; LT, lymphotoxin; NF, nuclear factor;
PNGase F, peptide 
 
N
 
-glycanase F; RANKL, receptor activator of NF-
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B
ligand; TRAIL, TNF-related apoptosis-inducing ligand; wt, wild-type. 
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and stimulation of neighboring cells. For example, CD40L
is important for B cell survival, proliferation, Ig isotype
switch, and differentiation (8), and the interaction of OX40
with OX40L is necessary for the differentiation of activated
B cells into high Ig-producing cells (9).
Here we characterize the structural and functional prop-
erties of a new ligand of the TNF cytokine family. The
new ligand, termed BAFF (B cell activating factor belong-
ing to the TNF family), appears to be expressed by T cells
and dendritic cells for the purpose of B cell costimulation,
and may therefore play an important role in the control of
B cell function.
 
Materials and Methods
 
Materials.
 
The anti-Flag M2 mAb, biotinylated anti-Flag M2
antibody, and the anti-Flag M2 antibody coupled to agarose were
purchased from Sigma Chemical Co. Cell culture reagents were
obtained from Life Sciences and BioWhittaker. Flag-tagged solu-
ble human APRIL (a proliferation inducing ligand; residues K
 
110
 
–
L
 
250
 
) was produced in 293 cells as described (10, 11). FITC-
labeled anti-CD4, anti-CD8, and anti-CD19 antibodies were
purchased from PharMingen. Goat F(ab
 
9
 
)
 
2
 
 specific for the Fc
 
5
 
m
 
fragment of human IgM were purchased from Jackson Immuno-
Research Laboratories. Secondary antibodies were obtained from
either PharMingen or Jackson ImmunoResearch Laboratories
and were used at the recommended dilutions.
 
Cells.
 
Human embryonic kidney 293 T cells (12) and fibro-
blast cell lines (see Table I) were maintained in DMEM contain-
ing 10% heat-inactivated FCS. Human embryonic kidney 293
cells were maintained in DMEM-nutrient mix F12 (1:1) supple-
mented with 2% FCS. T cell lines, B cell lines, and macrophage
cell lines (see Table I) were grown in RPMI supplemented with
10% FCS. Molt-4 cells were cultivated in Iscove’s medium sup-
plemented with 10% FCS. Epithelial cell lines were grown in
MEM-
 
a
 
 medium containing 10% FCS, 0.5 mM nonessential
amino acids, 10 mM Na-Hepes, and 1 mM Na pyruvate. Human
umbilical vein endothelial cells were maintained in M199 me-
dium supplemented with 20% FCS, 100 
 
m
 
g/ml of epithelial cell
growth factor (Collaborative Research, Inotech), and 100 
 
m
 
g/ml
of heparin sodium salt (Sigma Chemical Co.). All media con-
tained penicillin and streptomycin antibiotics.
PBLs were isolated from heparinized blood of healthy adult
volunteers by Ficoll-Paque (Amersham Pharmacia Biotech) gra-
dient centrifugation and cultured in RPMI, 10% FCS.
T cells were obtained from nonadherent PBLs by rosetting
with neuraminidase-treated sheep red blood cells and separated
from nonrosetting cells (mostly B cells) by Ficoll-Paque gradient
centrifugation. Purified T cells were activated for 24 h with phy-
tohemagglutinin (1 
 
m
 
g/ml; Sigma Chemical Co.), washed, and
cultured in RPMI, 10% FCS, 20 U/ml of IL-2. CD14
 
1
 
 mono-
cytes were purified by magnetic cell sorting using anti-CD14 an-
tibodies, goat anti–mouse-coated microbeads, and a Minimacs™
device (Miltenyi Biotech), and cultivated in the presence of GM-
CSF (800 U/ml, Leucomax
 
®
 
; Essex Chemie) and IL-4 (20 ng/ml;
Lucerna Chem) for 5 d, then with GM-CSF, IL-4, and TNF-
 
a
 
(200 U/ml; Bender) for an additional 3 d to obtain a CD83
 
1
 
,
dendritic cell–like population.
Human B cells of 
 
.
 
97% purity were isolated from peripheral
blood or umbilical cord blood using anti-CD19 magnetic beads
(M450; Dynal) as described (13).
 
Northern Blot.
 
Northern blot analysis was carried out using
Human Multiple Tissue Northern Blots I and II (7760-1 and
7759-1; Clontech). The membranes were incubated in hybrid-
ization solution (50% formamide, 2.5
 
3
 
 Denhardt’s, 0.2% SDS,
10 mM EDTA, 2
 
3
 
 SSC, 50 mM NaH
 
2
 
PO
 
4
 
, pH 6.5, 200 
 
m
 
g/ml
sonicated salmon sperm DNA) for 2 h at 60
 
8
 
C. Antisense RNA
probe containing the nucleotides corresponding to amino acids (aa)
136–285 of human BAFF (hBAFF) was heat denatured and added
at 2 
 
3 
 
10
 
6
 
 cpm/ml in fresh hybridization solution. The mem-
brane was hybridized 16 h at 62
 
8
 
C, washed once in 2
 
3
 
 SSC,
0.05% SDS (30 min at 25
 
8
 
C), once in 0.1
 
3
 
 SSC, 0.1% SDS (20
min at 65
 
8
 
C), and exposed at 
 
2
 
70
 
8
 
C to x-ray films.
 
Characterization of BAFF cDNA.
 
A partial sequence of hBAFF
cDNA was contained in several expressed sequence tag (EST)
clones (sequence data available from EMBL/GenBank/DDBJ
under accession nos. T87299 and AA166695) derived from fetal
liver and spleen and ovarian cancer libraries. The 5
 
9
 
 portion of the
cDNA was obtained by 5
 
9
 
 rapid amplification of cDNA ends
(RACE) PCR (Marathon-Ready cDNA; Clontech) with oligo-
nucleotides AP1 and JT1013 (5
 
9
 
-ACTGTTTCTTCTGGACCC-
TGAACGGC-3
 
9
 
) using the provided cDNA library from a pool
of human leukocytes as template, as recommended by the manu-
facturer. The resulting PCR product was cloned into PCR-0
blunt (Invitrogen) and subcloned as EcoRI-PstI fragment into
pT7T3 Pac vector (Amersham Pharmacia Biotech) containing
EST clone T87299. Therefore, full-length hBAFF cDNA was
obtained by combining 5
 
9
 
 and 3
 
9
 
 fragments using the internal PstI
site of BAFF. The sequence has been assigned EMBL/GenBank/
DDBJ accession no. AF116456.
A partial 617-bp sequence of murine BAFF was contained in
two overlapping EST clones (EMBL/GenBank/DDBJ accession
nos. AA422749 and AA254047). A PCR fragment spanning nu-
cleotides 158–391 of this sequence was used as a probe to screen a
mouse spleen cDNA library (Stratagene, Inc.). The sequence has
been assigned EMBL/GenBank/DDBJ accession no. AF119383.
 
Expression of Recombinant BAFF.
 
Full-length hBAFF was am-
plified using oligos JT1069 (5
 
9
 
-GACAAGCTTGCCACCATG-
GATGACTCCACA-3
 
9
 
) and JT637 (5
 
9
 
-ACTAGTCACAGCA-
GTTTCAATGC-3
 
9
 
). The PCR product was cloned into PCR-0
blunt and resubcloned as HindIII-EcoRI fragment into PCR-3
mammalian expression vector. A short version of soluble BAFF
(sBAFF/short, aa Q136–L285) was amplified using oligos JT636
(5
 
9
 
-CTGCAGGGTCCAGAAGAAACAG-3
 
9
 
) and JT637. A long
version of sBAFF (sBAFF/long, aa L83–L285) was obtained from
full-length BAFF using internal PstI site. sBAFFs were resub-
cloned as PstI-EcoRI fragments behind the hemagglutinin signal
peptide and Flag sequence of a modified PCR-3 vector, and as
PstI-SpeI fragments into a modified pQE16 bacterial expression
vector in frame with an NH
 
2
 
-terminal Flag sequence (14). Con-
structs were sequenced on both strands.
The establishment of stable 293 cell lines expressing the short
soluble form or full-length BAFF, and the expression and purifi-
cation of recombinant sBAFF from bacteria and mammalian 293
cells were performed as described
 
 
 
(14, 15).
 
Reverse Transcriptase PCR.
 
Total RNA extracted from T cells,
B cells, in vitro–derived immature dendritic cells, 293 wild-type
(wt) and 293-BAFF (full-length) cells was reverse transcribed us-
ing the Ready to Go system (Amersham Pharmacia Biotech) accord-
ing to the manufacturer’s instructions. BAFF and 
 
b
 
-actin cDNAs
were detected by PCR amplification with Taq DNA polymerase
(steps of 1 min each at 94
 
8
 
C, 55
 
8
 
C, and 72
 
8
 
C for 30 cycles) using
specific oligonucleotides: for BAFF, JT1322 5
 
9
 
-GGAGAAG-
GCAACTCCAGTCAGAAC-3
 
9
 
 and JT1323 5
 
9
 
-CAATTCATC- 
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CCCAAAGACATGGAC-3
 
9
 
; for IL-2 receptor 
 
a
 
 chain, JT1368
5
 
9
 
-TCGGAACACAACGAAACAAGTC-3
 
9
 
 and JT1369 5
 
9
 
-CTT-
CTCCTTCACCTGGAAACTGACTG-3
 
9
 
; and for 
 
b
 
-actin,
5
 
9
 
-GGCATCGTGATGGACTCCG-3
 
9
 
 and 5
 
9
 
-GCTGGAAGGT-
GGACAGCGA-3
 
9
 
.
 
Gel Permeation Chromatography.
 
293 T cells were transiently
transfected with the short form of sBAFF and grown in serum-
free Optimem medium for 7 d. Conditioned supernatants were
concentrated 20 times, mixed with internal standards catalase and
OVA, and loaded onto a Superdex-200 HR10/30 column. Pro-
teins were eluted in PBS at 0.5 ml/min, and fractions (0.25 ml)
were precipitated with TCA and analyzed by Western blotting
using anti-Flag M2 antibody. The column was calibrated with
standard proteins: ferritin (440 kD), catalase (232 kD), aldolase
(158 kD), BSA (67 kD), OVA (43 kD), chymotrypsinogen A
(25 kD), and ribonuclease A (13.7 kD).
 
PNGase F Treatment.
 
Samples were heated in 20 
 
m
 
l of 0.5%
SDS, 1% 2-ME for 3 min at 95
 
8
 
C, then cooled and supplemented
with 10% NP-40 (2 
 
m
 
l), 0.5 M sodium phosphate, pH 7.5 (2 
 
m
 
l),
and Peptide 
 
N
 
-glycanase F (PNGase F; 125 U/
 
m
 
l, 1 
 
m
 
l, or no
enzyme in controls). Samples were incubated for 3 h at 37
 
8
 
C be-
fore analysis by Western blotting.
 
Edman Sequencing.
 
293 T cells were transiently transfected with
the long form of sBAFF and grown in serum-free Optimem me-
dium for 7 d. Conditioned supernatants were concentrated 20 times,
fractionated by SDS-PAGE, and blotted onto polyvinylidene difluo-
ride membrane (Bio-Rad Laboratories) as described previously (16),
and then sequenced using a gas phase sequencer (ABI 120A; Perkin
Elmer) coupled to an analyzer (ABI 120A; Perkin Elmer) equipped
with a phenylthiohydantoin C18 2.1 
 
3
 
 250 mm column. Data were
analyzed using ABI 610 software (Perkin Elmer).
 
Antibodies.
 
Polyclonal antibodies were generated by immu-
nizing rabbits (Eurogentec) with recombinant sBAFF/long. Spleens
of rats immunized with the same antigen were fused to x63Ag8.653
mouse myeloma cells, and hybridomas were screened for BAFF-
specific IgGs. One of these mAbs, 43.9, is an IgG2a that specifically
recognizes hBAFF.
 
FACS
 
®
 
.
 
Cells were stained in 50 
 
m
 
l of FACS buffer (PBS,
10% FCS, 0.02% NaN
 
3
 
) with 50 ng (or the indicated amount) of
Flag-tagged short soluble hBAFF for 20 min at 4
 
8
 
C, followed by
anti-Flag M2 (1 
 
m
 
g) and secondary antibody. Anti-BAFF mAb
43.9 was used at 40 
 
m
 
g/ml. For two-color FACS
 
® analysis,
peripheral blood lymphocytes were stained with Flag-tagged
sBAFF/long (2 mg/ml), followed by biotinylated anti-Flag M2
(1:400) and PE-labeled streptavidin (1:100), followed by FITC-
labeled anti-CD4, anti-CD8, or anti-CD19.
PBL Proliferation Assay. PBLs were incubated in 96-well plates
(105 cells/well in 100 ml RPMI supplemented with 10% FCS) for
72 h in the presence or absence of 2 mg/ml of goat anti–human m
chain antibody (Sigma Chemical Co.) or control F(ab9)2 and with
the indicated concentration of native or boiled sBAFF/long. Cells
were pulsed for an additional 6 h with [3H]thymidine (1 mCi/well)
and harvested. [3H]Thymidine incorporation was monitored by
liquid scintillation counting. In some experiments, recombinant
sBAFF was replaced by 293 cells stably transfected with full-
length BAFF (or 293 wild-type [wt] as control) that had been
fixed for 5 min at 258C in 1% paraformaldehyde. Assay was per-
formed as described (17). In further experiments, CD191 cells
were isolated from PBLs with magnetic beads, and the remaining
CD192 cells were irradiated (3,000 rads) before reconstitution
with CD191 cells. Proliferation assay with sBAFF was then per-
formed as described above.
B Cell Activation Assay. Purified B cells were activated in the
EL-4 culture system as described (13). In brief, 104 B cells mixed
with 5 3 104 irradiated murine EL-4 thymoma cells (clone B5)
were cultured for 5–6 d in 200 ml medium containing 5% vol/vol
of culture supernatants from human T cells (106/ml) which had
been activated for 48 h with PHA (1 mg/ml) and PMA (1 ng/ml).
B cells were then reisolated with anti-CD19 beads and cultured
for another 7 d (5 3 104 cells in 200 ml, duplicate or triplicate
Figure 1. (A) Predicted aa sequence of human and
mouse BAFF. The predicted transmembrane domain
(TMD, dashed line), the potential N-linked glycosylation
sites (stars), and the natural processing site of hBAFF (ar-
row) are indicated. The double line above hBAFF indi-
cates the sequence obtained by Edman degradation of the
processed form of hBAFF. (B) Comparison of the extracel-
lular protein sequence of BAFF and some members of the
TNF ligand family. Identical and homologous residues are
represented in black and shaded boxes, respectively. (C)
Dendrogram of TNF family ligands.1750 BAFF Stimulates B Cells
culture in flat-bottomed 96 well plates) in medium alone or in
medium supplemented with 5% T cell supernatants, or with 50
ng/ml IL-2 (a gift from the former Glaxo Institute for Molecular
Biology, Geneva) and 10 ng/ml each IL-4 and IL-10 (Pepro-
Tech), in the presence or absence of sBAFF. The anti-Flag M2
antibody was added at a concentration of 2 mg/ml and had no ef-
fect by itself.
Results
BAFF Is a Novel Ligand of the TNF Family. hBAFF was
identified by sequence homology as a possible novel mem-
ber of the TNF ligand family while we screened public
databases using an improved profile search (18). A cDNA
encoding the complete protein of 285 aa was obtained by
combining EST clones (covering the 39 region) with a
fragment (59 region) amplified by PCR. The absence of a
signal peptide suggested that BAFF was a type II membrane
protein that is typical of the members of the TNF ligand
family. The protein has a predicted cytoplasmic domain of
46 aa, a hydrophobic transmembrane region, and an extra-
cellular domain of 218 aa containing two potential N-gly-
cosylation sites (Fig. 1 A). The sequence of the extracellular
domain of BAFF shows highest homology with APRIL
(33% aa identity, 48% homology), whereas the identity
with other members of the family, such as TNF, FasL,
LTa, TRAIL (TNF-related apoptosis-inducing ligand), or
RANKL (receptor activator of NF-kB ligand) is ,20%
(Fig. 1, B and C). The mouse BAFF (mBAFF) cDNA clone
isolated from a spleen library encoded a slightly longer pro-
tein (309 aa) due to an insertion between the transmembrane
region and the first of several b strands which constitute the
receptor binding domain in all TNF ligand members (19).
This b strand–rich ectodomain is almost identical in mBAFF
and hBAFF (86% identity, 93% homology), suggesting that
the BAFF gene has been highly conserved during evolution
(Fig. 1 A).
BAFF Is Processed and Secreted. Although TNF fam-
ily members are synthesized as membrane-inserted ligands,
cleavage in the stalk region between transmembrane and
receptor binding domains is frequently observed. For exam-
ple, TNF and FasL are readily cleaved from the cell surface by
metalloproteinases (20, 21). While producing several forms
of recombinant BAFF in 293 T cells, we noticed that a re-
combinant soluble 32-kD form of BAFF (aa 83–285,
sBAFF/long), containing the complete stalk region and an
NH2-terminal Flag tag in addition to the receptor binding
domain, was extensively processed to a smaller 18-kD frag-
ment (Fig. 2, A and B). Cleavage occurred in the stalk re-
gion since the fragment was detectable only with antibodies
raised against the complete receptor interaction domain of
BAFF but not with anti-Flag antibodies (data not shown).
This experiment also revealed that only N124 (located in
the stalk) but not N242 (located at the entry of the F-b
sheet) was glycosylated, since the molecular mass of the
nonprocessed sBAFF/long was reduced from 32 to 30 kD
upon removal of the N-linked carbohydrates with PNGase
F, whereas the 18-kD cleaved form was insensitive to this
treatment. Peptide sequence analysis of the 18-kD frag-
ment indeed showed that cleavage occurred between R133
and A134 (Fig. 1 A). R133 lies at the end of a polybasic re-
gion that is conserved between human (R-N-K-R) and
mouse (R-N-R-R) BAFF. To test whether cleavage was
not merely an artifact of expressing soluble, nonnatural
forms of BAFF, membrane-bound full-length BAFF was
expressed in 293 T cells (Fig. 2 C). The 32-kD complete
BAFF and some higher molecular mass species (probably
Figure 2. Characterization of recombinant BAFF. (A) Schematic rep-
resentation of recombinant BAFF constructs. Soluble recombinant BAFFs
starting at Leu83 and Gln136 are expressed fused to an NH2-terminal Flag
tag and a 6–amino acid linker. The long form is cleaved between Arg133
and Ala134 (arrow) in 293 T cells, to yield a processed form of BAFF.
Asn124 and Asn242 belong to N-glycosylation consensus sites. N-linked
glycan present on Asn124 is shown as a Y. TMD, transmembrane domain.
(B) PNGase F treatment of recombinant BAFF. Concentrated superna-
tants containing Flag-tagged BAFFs and APRIL were deglycosylated and
analyzed by Western blotting using polyclonal anti-BAFF antibodies or
anti-Flag M2, as indicated. All bands except processed BAFF also reacted
with anti-Flag M2 (data not shown). (C) Full-length BAFF is processed to
a soluble form. 293 T cells were transiently transfected with full-length
BAFF. Transfected cells and their concentrated supernatants (S/N) were
analyzed by Western blotting using polyclonal anti-BAFF antibodies. Su-
pernatants corresponding to 10 times the amount of cells were loaded
onto the gel. (D) Size exclusion chromatography of sBAFF on Superdex-
200. Concentrated supernatants containing sBAFF/short were fraction-
ated on a Superdex-200 column, and the eluted fractions were analyzed
by Western blotting using anti-Flag M2 antibody. The migration posi-
tions of the molecular mass markers (in kD) are indicated on the left-hand
side for SDS-PAGE and at the top of the figure for size exclusion chro-
matography.1751 Schneider et al.
corresponding to nondissociated dimers and trimers) were
readily detectable in cellular extracts, but .95% of BAFF
recovered from the supernatant corresponded to the pro-
cessed 18-kD form, indicating that BAFF was also pro-
cessed when synthesized as a membrane-bound ligand.
Therefore, we engineered an sBAFF (Q136–L285,
sBAFF/short) whose sequence started 2 aa downstream of
the processing site (Fig. 1 B). As predicted, the Flag tag
attached to the NH2 terminus of this recombinant mole-
cule was not removed (data not shown), which allowed its
purification by an anti-Flag affinity column. To test its cor-
rect folding, the purified sBAFF/short was analyzed by gel
filtration where the protein eluted at an apparent molecular
mass of 55 kD (Fig. 2 D). We conclude that sBAFF/short
correctly assembles into a homotrimer (3 3 20 kD) in
agreement with the quaternary structure of other TNF
family members (19). Finally, unprocessed sBAFF/long was
readily expressed in bacteria, indicating that the cleavage
event was specific to eukaryotic cells.
Expression and Chromosomal Localization of BAFF. North-
ern blot analysis of BAFF revealed that the 2.5-kb BAFF
mRNA was abundant in the spleen and PBLs (Fig. 3 A).
Thymus, heart, placenta, small intestine, and lung showed
weak expression. This restricted distribution suggested that
cells present in lymphoid tissues were the main source of
BAFF. Through PCR analysis, we found that BAFF
mRNA was present in T cells and peripheral blood mono-
cyte–derived dendritic cells but not in B cells (Fig. 3 B).
Even naive, nonstimulated T cells appeared to express
some BAFF mRNA.
A sequence-tagged site (STS, SHGC-36171) was found
in the database which included the hBAFF sequence. This
site maps to human chromosome 13, in a 9-cM interval
between the markers D13S286 and D13S1315. On the cy-
togenetic map, this interval corresponds to 13q32-34. Of
the known TNF ligand family members, only RANKL
(Trance) has been localized to this chromosome (22)
though quite distant to BAFF (13q14).
BAFF Receptor Is Expressed on B Cells. For the ligand
to exert maximal biological effects, it was likely that the
BAFF receptor (BAFF-R) would be expressed either on
the same cells or on neighboring cells present in lymphoid
tissues. Using the recombinant sBAFF as a tool to specifi-
cally determine BAFF-R expression by FACS®, we indeed
found high levels of receptor expression in various B cell
lines, such as the Burkitt lymphomas Raji and BJAB (Fig.
4 A, and Table I). In contrast, cell lines of T cell, fibroblas-
tic, epithelial, and endothelial origin were all negative.
Very weak staining was observed with the monocyte line
THP-1, which, however, could be due to Fc receptor
binding. Thus, BAFF-R expression appears to be restricted
to B cell lines. The two mouse B cell lines tested were neg-
ative using the hBAFF as a probe, although weak binding
was observed on mouse splenocytes (data not shown). The
presence of BAFF-R on B cells was corroborated by analy-
Figure 3. Expression of BAFF. (A) Northern blots (2 mg poly A1
RNA per lane) of various human tissues were probed with BAFF anti-
sense mRNA. (B) Reverse transcriptase amplification of BAFF, IL-2 re-
ceptor a chain (IL2-Ra), and actin from RNA of purified blood T cells
at various time points of PHA activation, E-rosetting–negative blood cells
(mostly B cells), in vitro–derived immature dendritic cells, 293 cells, and
293 cells stably transfected with full-length BAFF (293-BAFF). Control
amplifications were performed in the absence of added cDNA. IL-2 re-
ceptor a chain was amplified as a marker of T cell activation.
Figure 4. BAFF binds to mature B cells. (A) Binding of sBAFF to BJAB
and Jurkat cell lines, and to purified CD191 cells of cord blood. Cells were
stained with the indicated amount (in ng/50 ml) of Flag-BAFF and analyzed
by flow cytometry. (B) Binding of sBAFF to PBLs. PBLs were stained with
anti-CD8–FITC or with anti-CD19–FITC (x axis) and with Flag-BAFF
plus M2-biotin and avidin-PE (y axis). Flag-BAFF was omitted in controls.1752 BAFF Stimulates B Cells
sis of umbilical cord and peripheral blood lymphocytes. While
CD81 and CD41 T cells lacked BAFF-R (Fig. 4 B, and data
not shown), abundant staining was observed on CD191 B
cells (Fig. 4, A and B), indicating that BAFF-R is expressed on
all blood B cells, including naive and memory B cells. No evi-
dence was obtained for a CD191, BAFF-R2 population.
BAFF Can Costimulate B Cell Growth. Since BAFF
bound to blood-derived B cells, experiments were per-
formed to determine whether the ligand could deliver
growth-stimulatory or growth-inhibitory signals. PBLs
were stimulated with anti-IgM (m) antibodies together
with fixed 293 cells stably expressing surface BAFF (Fig.
5 A). The levels of [3H]thymidine incorporation induced
by anti-m alone were not altered by the presence of control
cells but were increased twofold in the presence of BAFF-
transfected cells (Fig. 5 B). A dose-dependent proliferation
of PBLs was also obtained when BAFF-transfected cells
were replaced by purified sBAFF (Fig. 5 C), indicating that
BAFF does not require membrane attachment to exert its
activity. In this experimental setup, proliferation induced
by sCD40L required concentrations .1 mg/ml, but was
less dependent on the presence of anti-m than that medi-
ated by BAFF (Fig. 5 D). When purified CD191 B cells
were cocultured with irradiated autologous CD192 PBLs,
costimulation of proliferation by BAFF was unaffected,
demonstrating that [3H]thymidine uptake was mainly due
to B cell proliferation and not to an indirect stimulation of
another cell type (data not shown). The observed B cell
proliferation in response to BAFF was entirely dependent
on the presence of anti-m antibodies, indicating that BAFF
functioned as costimulator of B cell proliferation.
To investigate a possible effect of BAFF on preplasma,
germinal center–like B cells (13), purified peripheral or cord
blood B cells were preactivated by coculture with EL-4 T
cells in the presence of a cytokine mixture from superna-
tants of PHA/PMA-stimulated T cells (23). These B cells
were reisolated to 98% purity and yielded a twofold in-
crease in secreted Ig during a secondary culture in the pres-
ence of BAFF and activated T cell cytokines compared
with cytokines alone. No significant effect was seen in the
absence of exogenous cytokines, and an intermediate (1.5-
fold) effect was observed in the presence of the recombi-
nant cytokines IL-2, IL-4, and IL-10 (Fig. 5, E and F).
Discussion
Here we report the molecular cloning, expression, and
biological activity of a new member of the TNF ligand
Table I. Binding of sBAFF to Various Cell Lines
Cell type Cell lines BAFF binding Specific details
Epithelial-like HT-29 2 Colon adenocarcinoma
A375 2/1 Melanoma
MCF-7 2 Breast adenocarcinoma
Me260 2 Melanoma
Cos 1 Monkey kidney cells
Fibroblasts WI-38 2 Lung
Hs-68 2 Foreskin
Hs-27 2 Foreskin
Endothelial cells HUVEC 2 Umbilical vein
Macrophages/monocytes THP-1 2/1 Monocyte
T cell lines Molt-4 2 Lymphoblastic leukemia
Hut-78 2 Cutaneous lymphoma
Jurkat 2 Lymphoblastic leukemia
B cell lines BJAB 111 Burkitt lymphoma
Namalawa 11 Burkitt lymphoma
Daudi 1/2 Burkitt lymphoma EBNA1 VCA1
Ramos 11 Burkitt lymphoma EBV2
Raji 111 Burkitt lymphoma
JIYOYE 1 Burkitt lymphoma
SKW.64 11 IgM secreting EBV1
RPMI 1788 111 Peripheral blood, IgM secreting
IM-9 111 Lymphoblast Ig secreting
NC-37 111 Lymphoblast EBV1
Mouse cell lines WEHI-231 2 B cell lymphoma
A20 2 B cell lymphoma1753 Schneider et al.
family. The human and mouse sequences exhibit the typi-
cal characteristics of this family, i.e., a type II membrane
protein organization and the conservation of nine b sheets,
which fold into a “jelly-roll” structure that trimerizes to
form receptor interacting sites. The biochemical analysis of
BAFF is also consistent with the typical homotrimeric
structure of TNF family members. In this family of ligands,
BAFF exhibits the highest level of sequence similarity with
APRIL, which we have recently characterized as a ligand
stimulating growth of various tumor cells (11). Unlike
TNF and LTa, which are two family members with
equally high homology (33% identity) and whose genes
are linked on chromosome 6, APRIL and BAFF are not
clustered on the same chromosome. APRIL is located on
chromosome 17 (our unpublished data), whereas BAFF
maps to the distal arm of human chromosome 13 (13q34).
Abnormalities in this locus were characterized in Burkitt
lymphomas as the second most frequent defect (24) besides
the translocation involving the myc gene into the Ig locus
(25). Considering the high expression levels of BAFF-R on
all Burkitt lymphoma cell lines analyzed (see Table I), this
raises the intriguing possibility that some Burkitt lympho-
mas may have deregulated BAFF expression, thus stimulat-
ing growth in an autocrine manner.
B cell growth was efficiently costimulated with recombi-
nant sBAFF lacking the transmembrane domain. This ac-
tivity is in contrast to several TNF family members that are
active only as membrane-bound ligands, such as TRAIL,
FasL, and CD40L. Soluble forms of these ligands have poor
biological activity that can be enhanced by their cross-link-
ing, thereby mimicking the membrane-bound ligand (15).
In contrast, cross-linking Flag-tagged sBAFF with anti-Flag
antibodies or the use of membrane-bound BAFF expressed
on the surface of epithelial cells did not further enhance the
mitogenic activity of BAFF, suggesting that it can act sys-
temically as a secreted cytokine, like TNF does. This is in
agreement with the observation that a polybasic sequence
present in the stalk of BAFF acted as a substrate for a pro-
Figure 5. BAFF costimulates B cell proliferation. (A) Surface expression of BAFF in stably transfected 293 cells. 293-BAFF and 293 wt cells were
stained with anti-BAFF mAb 43.9 and analyzed by flow cytometry. (B) Costimulation of PBLs by 293-BAFF cells. PBLs (105/well) were incubated with
15,000 paraformaldehyde-fixed 293 cells (293 wt or 293-BAFF) in the presence or absence of anti-B cell receptor antibody (anti-m). Fixed 293 cells alone
incorporated 100 cpm. (C) Dose-dependent costimulation of PBL proliferation by sBAFF in the presence of anti-m. Proliferation was determined after 72 h
incubation by [3H]thymidine incorporation. Controls include cells treated with BAFF alone, with heat-denatured BAFF, or with an irrelevant isotype-
matched antibody in place of anti-m. (D) Comparison of (co)stimulatory effects of sCD40L and sBAFF on PBL proliferation. Experiment was performed
as described in panel C. (E) BAFF costimulates Ig secretion of preactivated human B cells. Purified CD191 B cells were activated by coculture with EL-4
T cells and activated T cell supernatants for 5–6 d, then reisolated and cultured for another 7 d in the presence of medium only (2) or containing 5%
activated T cell supernatants (T-SUP) or a blend of cytokines (IL-2, IL-4, IL-10). The columns represent means of Ig concentrations for cultures with or
without 1 mg/ml BAFF. Means of fold increase 6 SD were 1.23 6 0.11 for medium only, 2.06 6 0.18 with T cell supernatants (four experiments), and
1.45 6 0.06 with IL-2, IL-4, and IL-10 (two experiments). These were performed with peripheral blood (three experiments) or cord blood B cells (one
experiment; 2.3-fold increase with T cell supernatants, 1.5-fold increase with IL-2, IL-4, and IL-10). (F) Dose–response curve for the effect of BAFF in
cultures with T cell supernatants, as shown in panel D. Mean 6 SD of three experiments.1754 BAFF Stimulates B Cells
tease. Similar polybasic sequences are also present at corre-
sponding locations in both APRIL and TWEAK (Apo-3L),
and for both of them there is evidence of proteolytic pro-
cessing (26; Holler, N., and J. Tschopp, unpublished obser-
vation). Although the protease responsible for the cleavage
remains to be determined, it is unlikely to be the metallo-
proteinase responsible for the release of membrane-bound
TNF, as their sequence preferences differ completely (21).
The multibasic motifs in BAFF (R-N-K-R), APRIL (R-
K-R-R), and TWEAK (R-P-R-R) are reminiscent of the
minimal cleavage signal for furin (R-X-K/R-R), the pro-
totype of a proprotein convertase family (27).
The role of antigen-specific B lymphocytes during the
different stages of the immune response is highly dependent
on signals and contacts from helper T cells (28) and anti-
gen-presenting cells such as dendritic cells (29). B lympho-
cytes first receive these signals early on during the immune
response when they interact with T cells at the edge of the
B cell follicles in lymphoid tissues, leading to their prolifer-
ation and differentiation into low-affinity antibody-form-
ing cells (30). At the same time, some antigen-specific B
cells also migrate to the B cell follicle and contribute to the
formation of germinal centers, another site of B cell prolif-
eration but also affinity maturation and generation of mem-
ory B cells and high-affinity plasma cells (31).
Signals triggered by CD40L have been shown to be crit-
ical for the function of B lymphocytes at multiple steps of
the T cell–dependent immune response (32). However,
several studies clearly showed that CD40L–CD40 interac-
tion does not account for all contact-dependent T cell help
for B cells. Indeed, CD40L-deficient T cells isolated from
either knockout mice or patients with X-linked hyper IgM
syndrome have been shown to successfully induce prolifer-
ation of B cells and their differentiation into plasma cells
(33). Likewise, studies using blocking antibodies against
CD40L showed that a subset of surface IgD1 B cells iso-
lated from human tonsils proliferate and differentiate in re-
sponse to activated T cells in a CD40-independent manner
(34). Other members of the TNF family, such as mem-
brane-bound TNF and CD30L, have also been shown to
be involved in a CD40- and surface Ig–independent stimu-
lation of B cells (33, 35). Finally, CD40-deficient B cells
can be stimulated to proliferate and differentiate into plasma
cells by helper T cells as long as the surface B cell receptors
are triggered at the same time (36). BAFF as well as CD30L
and CD40L is expressed by T cells, but its uniqueness re-
sides in its expression by dendritic cells as well as the highly
specific location of its receptor on B cells in contrast to the
wider expression patterns of CD40, CD30, and the TNF
receptors (37). Hence, BAFF may uniquely affect B cells.
In support of a role for BAFF in T cell– and/or dendritic
cell–induced B cell growth and potential maturation, we
found that BAFF costimulates proliferation of blood-
derived B cells concomitantly with cross-linking of the B
cell receptors. Moreover, using CD191 B cells differenti-
ated in vitro into preplasma, germinal center–like B cells
(13), we observed a costimulatory effect of BAFF on Ig
production by these B cells in the presence of cytokines
from activated T cells. Thus, BAFF can induce signals in
both naive B cells and germinal center–committed B cells
in vitro. Whether this observation will translate during a
normal immune response or not will have to be addressed
by proper in vivo experiments.
The biological responses induced in B cells by BAFF are
distinct from that of CD40L, since proliferation triggered
by CD40L occurred at a lower level independently of an
anti-m costimulus (17; Fig. 5 D). Moreover, CD40L can
counteract apoptotic signals in B cells after engagement of
the B cell receptor (38), whereas BAFF was not able to res-
cue the B cell line Ramos from anti-m–mediated apoptosis,
despite the fact that Ramos cells do express BAFF-R (Ta-
ble I; MacKay, F., unpublished observations). Therefore, it
is likely that CD40L and BAFF fulfill distinct functions. In
this respect, it is noteworthy that BAFF did not interact
with any of 16 recombinant receptors of the TNF family
tested, including CD40 (Schneider, P., and J. Tschopp, un-
published observations).
Several obscure zones remain in our understanding of an
immune response. For instance, little is known about the
mechanisms governing the differentiation of a B cell into a
plasma cell versus a germinal center B cell. Similarly, aside
from the possible involvement of the CD40 pathway
shown in vitro (39), we have very little information about
the signals deciding the differentiation of a germinal center
B cell into a memory B cell or a plasma cell. It will be very
interesting to investigate whether or not BAFF has any
unique role to play in these critical checkpoint decisions.
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